Healthcare stocks are moderately lower, with the NYSE Healthcare
Sector Index falling about 0.4% and shares of healthcare companies
in the S&P 500 slipping 0.4% as a group.
In company news, Nxstage Medical (
) is down more than 17% at $10.24 a share, sliding to its worst
price since March 2010 after the home-dialysis company disappointed
investors with its Q3 earnings and guided its Q4 results below
NXTM turned in a net of $0.08 per share, lagging the Capital IQ
consensus by $0.02. Revenue rose 9.5% year over year to $66.9
million, edging out the analysts' view by around $140,000.
The medical device manufacturer is projecting a Q4 net loss of
$0.08 to $0.10 per share, or at least $0.03 wider than the analyst
consensus. Revenue is seen in a range of $67 million to $68.5
million, trailing estimates by at least $2.73 million. NXTM
executives also said they are hoping for 15% growth in the
company's home-based revenue as a result of increased
direct-to-patient marketing and other initiatives.
In other sector news,
(+) GERN, (+57.8%) Mayo Clinic study of its Imetelstat drug
candidate found an overall response of 44% in the 18 patients with
myelofibrosis evaluable for response, including four patients with
complete remissions and another with a partial remission.
(-) BIOS (-17.5%) Break-even Q3, ex items, trails Street view by
$0.03. Lowers top end of FY13 revenue forecast by $15 mln to a new
range of $830 mln to $850 mln - still in-line with estimates
expecting $839.34 mln in revenue.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.